Lindsay Elbaum
Interventional Cardiology · Springfield, NJNPI 1639596984
Payments from drug & device makers
What this record shows
This record is dominated by grants: $22,500 of the $27,897 with a category attached, or 80.7%. 18 manufacturers reported payments, led by Medtronic at 56.0% of the total. Reporting peaked in 2020 at $23,286 and has fallen 95.2% since, to $1,110 in 2025.
Across 119 payments — averaging $234.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Abbott$8K
- Inari Medical, Inc.$1K
- Boston Scientific$645
- Shockwave Medical, Inc$458
- Stryker$417
- plus $999 from 12 others
What the payments were for
- Grants$22,50081%
- Food & beverage$5,22319%
- Education$1741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 26 | $15,630 |
| Abbott | 20 | $8,406 |
| Inari Medical, Inc. | 22 | $1,343 |
| Boston Scientific | 17 | $645 |
| Shockwave Medical, Inc | 3 | $458 |
| Stryker | 5 | $417 |
| AstraZeneca | 9 | $385 |
| Amgen | 3 | $151 |
| Endologix LLC | 1 | $150 |
| Edwards Lifesciences | 2 | $64 |
| Johnson & Johnson | 2 | $49 |
| Abiomed | 1 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $43 |
| Bridgebio Pharma, Inc. | 2 | $34 |
| Angiodynamics, Inc. | 1 | $24 |
| Bayer | 1 | $22 |
| Terumo Medical Corporation | 1 | $17 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,897 in reported general payments places this provider in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 17 | $20,021 |
| JardianceEmpagliflozin | 16 | $15,676 |
| EliquisApixaban | 12 | $11,973 |
| Metoprolol Succinate | 19 | $354 |
| Losartan Potassium | 16 | $123 |
| Furosemide | 13 | $86 |
| Atorvastatin Calcium | 20 | $86 |
| Carvedilol | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $11,97312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Springfield
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
- Dimitrios KarmpaliotisMorristown$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.